Brought to you by 
Ipsen, Inspiration sell off IB1001 assets to Cangene Corp.
01 Mar 2013
Executive Summary
Inspiration Biopharmaceuticals Inc. and Ipsen have granted specialty pharmaco Cangene Corp. (majority owned by Apotex Inc.) global rights to IB1001, a recombinant factor IX (rFIX) for hemophilia B that is under regulatory review in the US and Europe.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ipsen, Inspiration sell off IB1001 assets to Cangene Corp.
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice